ADD PROGRAM SYMPOSIUM

添加议程研讨会

• 批准号: 8973145
• 负责人: Karen S Wilcox
• 金额: $ 2万
• 依托单位: UNIVERSITY OF UTAH
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-04-01 至 2016-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8973145
• 关键词: Academia; Acute; Address; Anticonvulsants; Awareness; Basic Science; Big Data; Cities; Clinical; Collaborations; Development; Disease; Epilepsy; Epileptogenesis; FDA approved; Faculty; Functional disorder; Funding; Future; Goals; Industry; Institutes; Intractable Epilepsy; Knowledge; Modality; Outcome; Patients; Persons; Pharmaceutical Preparations; Prevention; Printing; Refractory; Request for Applications; Research; Research Personnel; Risk; Science; Seizures; Services; Structure; Technology; Therapeutic; Time; Travel; Universities; Utah; Visual; drug development; effective therapy; high risk; innovation; insight; medical specialties; meetings; nervous system disorder; novel strategies; prevent; programs; public health relevance; public-private partnership; symposium; therapy development

 DESCRIPTION (provided by applicant): The Anticonvulsant Drug Development (ADD) Program will host a symposium entitled "Therapy Development in the Era of Team Science and Big Data: What Will the Future Bring to the Patient with Epilepsy"? This symposium will be held from May 17th, 2015 - May 20th, 2015 in Park City, UT and will be open to the public. Despite FDA approval of over 16 anticonvulsant drugs in the last two decades, nearly 1/3 of all patients with epilepsy fail to achieve full seizure control. In addition, it is currently not possible to prvent the development of epilepsy in patients at high risk following a CNS insult. Therefore, there is an acute need for more effective therapies for the patient with intractable epilepsy and for persons at risk. The goal of the symposium is to explore how innovative breakthroughs in basic science can be leveraged by public, federal, and private partnerships to rapidly develop new treatments for the patient with epilepsy. A creative conference structure, ample discussion time, and inclusion of junior investigators in all aspects of the meeting will insure that new knowledge, new collaborations, and new insight into state of the art therapy development will be significant outcomes of the symposium. This application requests funds to partially support travel for the invited faculty and junior investigators and to provide funds for conference services, printing, and audio-visual technologies.

 描述（由申请人提供）：抗惊厥药物开发（ADD）计划将举办题为“团队科学和大数据时代的治疗开发：未来将给癫痫患者带来什么”的研讨会？本次研讨会将于2015年5月17日至2015年5月20日在犹他州帕克城举行，并向公众开放。 尽管FDA在过去二十年中批准了超过16种抗惊厥药物，但近1/3的癫痫患者未能完全控制癫痫发作。此外，目前还不可能防止中枢神经系统损伤后高风险患者发生癫痫。因此，有一个 迫切需要对难治性癫痫患者和高危人群进行更有效的治疗。研讨会的目标是探讨如何在基础科学的创新突破可以利用公共，联邦和私人合作伙伴关系，以迅速开发新的治疗癫痫患者。一个创造性的会议结构，充足的讨论时间，并在会议的各个方面包括初级研究人员将确保新的知识，新的 合作以及对最新疗法发展的新见解将是研讨会的重要成果。该申请要求资金部分支持受邀教师和初级调查员的差旅费，并为会议服务、印刷和视听技术提供资金。